Citation: borger et al.Twenty-year results of the hancock ii bioprosthesis.J heart valve dis.2006 jan;15(1):49-55.Earliest date of publish used for event date.No unique device identifier (serial/lot) numbers were provided; without this information, it could not be determined whether these observations have been previously reported.Without return of the product no definitive conclusion can be made regarding the clinical observations.If information is provided in the future, a supplemental report will be issued.
|
Medtronic received information via literature regarding 20-year results of hancock ii porcine bioprosthetic valve in a large patient population.All data were collected by mail and/or telephone questionnaire for patients who underwent surgery between 1982 and 2001.The study population included 1,569 patients (predominantly male, mean age 67 years), all of which were implanted with medtronic hancock ii porcine bioprosthetic valve in the atrial (1,010) or mitral (559) position.No serial numbers provided.Among all patients, adverse events included: thromboembolism/stroke/transient ischemic attack, endocarditis, major bleeding, structural valve dysfunction (svd), aneurysm/dissection, paravalvular leak, and valve-related reoperation.Based on the available information medtronic product may have been associated with the adverse event(s).No additional adverse patient effects or product performance issues were reported.
|